Day C E, Schurr P E, Heyd W E, Lednicer D
Adv Exp Med Biol. 1976;67(00):231-249. doi: 10.1007/978-1-4614-4618-7_14.
A new -ind of pharmacologic activity called hypobetalipoproteinemia is described. Iperationally the activity consists of a marked reduction of heparin precipitating lipoproteins (beta and/or pre-beta electrophoretic mobility) in hypercholesterolemic animals with a simultaneous decrease in the heparin precipitating lipoprotein: cholesterol ratio. As determined by ultracentrifugal fractionation of the lipoproteins from hypercholesterolemic rat serum, this activity consists of both a reduction in heparin precipitating lipoproteins and an increase high density lipoproteins that are not precipitated by heparin. Changes in composition were also induced in both lipoprotein fractions. The greatest changes were observed for free and esterified cholesterol, which were markedly reduced in the heparin precipitating lipoproteins and concomitantly increased in the high density lipoproteins. The hypobetalipoproteinemic agent exhibiting this activity is 1-[p-(1'-adamantyloxy) phenyl]-piperidine (U-41792). This agent is active in hypercholesterolemic rats, mice, quail, and pigeons.
描述了一种名为低β脂蛋白血症的新型药理活性。从操作上来说,该活性表现为在高胆固醇血症动物中,肝素沉淀脂蛋白(β和/或前β电泳迁移率)显著降低,同时肝素沉淀脂蛋白与胆固醇的比率也降低。通过对高胆固醇血症大鼠血清脂蛋白进行超速离心分级分离确定,这种活性既包括肝素沉淀脂蛋白的减少,也包括未被肝素沉淀的高密度脂蛋白的增加。两种脂蛋白组分的组成也发生了变化。在游离胆固醇和酯化胆固醇方面观察到的变化最大,它们在肝素沉淀脂蛋白中显著减少,而在高密度脂蛋白中则相应增加。表现出这种活性的低β脂蛋白血症药物是1-[对-(1'-金刚烷氧基)苯基]-哌啶(U-41792)。该药物在高胆固醇血症大鼠、小鼠、鹌鹑和鸽子中均有活性。